Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. (Q37316015)

19 August 2017

1 reference

title

Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. (English)

1 reference

19 August 2017

Ener Cagri Dinleyici

1

1 reference

PubMed ID

18980540

19 August 2017

Zeynel Abidin Yargic

series ordinal

2

1 reference

19 August 2017

1 November 2008

1 reference

Expert Review of Vaccines

19 August 2017

1 reference

19 August 2017

7

1 reference

19 August 2017

9

1 reference

19 August 2017

1367-1394

1 reference

Pneumococcal vaccination in developing countries.

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Pneumococcal otitis media and pneumococcal vaccines, a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein--conjugated pneumococcal vaccine in Filipino infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Impact of conjugate pneumococcal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

The potential indirect effect of conjugate pneumococcal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Potential impact of conjugate pneumococcal vaccines on pediatric pneumococcal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Changing epidemiology of outpatient bacteremia in 3- to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

A role for Streptococcus pneumoniae in virus-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Changes in frequency and pathogens causing acute otitis media in 1995-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Impact of the pneumococcal conjugate vaccine on otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effect of pneumococcal vaccination on quality of life in children with recurrent acute otitis media: a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effect of pneumococcal vaccination on otitis media with effusion in children older than 1 year.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Pneumococcal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug resistance of Streptococcus pneumoniae in healthy children attending day-care centers in Lisbon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in HIV-Infected and HIV-uninfected childre

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Diversity and Antibiotic Resistance among Nonvaccine Serotypes ofStreptococcus pneumoniaeCarriage Isolates in the Post–Heptavalent Conjugate Vaccine Era

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Serotype-specific problems associated with pneumococcal conjugate vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Emergence of a serotype 1 Streptococcus pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Streptococcus pneumoniae serotype 19A in children, South Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B,

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Vaccines in the era of genomics: the pneumococcal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

RANDOMIZED, CONTROLLED TRIAL EFFICACY OF PNEUMOCOCCAL CONJUGATE VACCINE AGAINST OTITIS MEDIA AMONG NAVAJO AND WHITE MOUNTAIN APACHE INFANTS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effect of Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization among Immunized and Unimmunized Children in a Community‐Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Effect of Community‐Wide Conjugate Pneumococcal Vaccine Use in Infancy on Nasopharyngeal Carriage through 3 Years of Age: A Cross‐Sectional Study in a High‐Risk Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

Emergence of Vaccine-Related Pneumococcal Serotypes as a Cause of Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1367

10.1586/14760584.7.9.1367

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18980540